KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Pharmacology, Toxicology and Pharmaceutical Science
1
7%
Immunology and Microbiology
1
7%
Unknown
10
67%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2023.
All research outputs
#2,229,026
of 23,549,388 outputs
Outputs from Journal of Clinical Oncology
#5,170
of 20,432 outputs
Outputs of similar age
#49,400
of 352,015 outputs
Outputs of similar age from Journal of Clinical Oncology
#122
of 565 outputs
Altmetric has tracked 23,549,388 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,432 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.1. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,015 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 565 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.
